CXCR4 and breast carcinoma: As was seen previously [19], the (CK+/JUNB+/CXCR4+) phenotype was also the most predominant phenotype (90%) in DTCs from breast cancer patients, followed by the (CK+/JUNB+/CXCR4–) in 36% and the (CK+/JUNB–/CXCR4–) in 31%, while the (CK+/JUNB–/CXCR4+) was the less frequent (5%), concluding that the phenotypic patterns were similar in both NSCLC and breast cancer cases.